Categories Analysis, Consumer

Earnings preview: What to expect when Procter & Gamble reports Q4 results

The Procter & Gamble Company (NYSE: PG) is scheduled to report fourth quarter 2019 earnings results on Tuesday, July 30, before market open. Analysts expect the company to report earnings of $1.05 per share on revenue of $16.8 billion. Both revenue and earnings are expected to increase on a year-over-year basis.

In the trailing four quarters, the company has consistently topped earnings estimates. P&G has a strong product portfolio which is an advantage. A favorable product mix coupled with pricing and volumes are expected to generate higher organic sales in the fourth quarter. The company is seeing healthy growth in the domestic market which could benefit the topline.

Procter & Gamble reports third quarter 2019 earnings

Organic sales growth and a lower effective tax rate are likely to help the top and bottom line numbers in the fourth quarter. However, higher costs and negative currency impacts could dampen the quarterly results.

In the third quarter of 2019, P&G topped market expectations on revenue and earnings, with a 1% growth in net sales and a 6% increase in adjusted EPS. Organic sales rose 5%, driven by a 2% increase in organic shipment volume. Sales grew across all its segments, with the exception of grooming and baby care.

For fiscal-year 2019, P&G has guided for total sales to be flat to up 1% versus 2018. Organic sales is expected to grow 4%. GAAP EPS is expected to increase 17-24% versus last year while core EPS is expected to grow 3-8%.

In the trailing 52 weeks, P&G’s shares have gained 43%. Year-to-date, the stock has risen 25%. The majority of analysts have rated the stock a Buy while none have rated it Sell. TipRanks has given the stock an average price target of $115.25.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

What to expect when J.M. Smucker (SJM) reports Q2 2025 earnings results

Shares of The J.M. Smucker Co. (NYSE: SJM) stayed red on Friday. The stock has dropped 6% over the past three months. The branded foods company is slated to report

Earnings Summary: Highlights of BJ’s Wholesale Club’s Q3 2024 results

Department store chain BJ’s Wholesale Club Holdings, Inc. (NYSE: BJ) has reported financial results for the third quarter of 2024, reporting a 3% increase in net sales. Adjusted earnings, on a

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top